American Innovation and R&D Competitiveness Act of 2025

1) What happened: On March 10, 2025, Rep. Estes (R-KS) introduced HR1990 to restore immediate expensing for qualified R&D costs under IRC §174. The Tax Cuts and Jobs Act of 2017 required R&D costs to be amortized over 5 years (US) or 15 years (foreign) starting in 2022 — this bill would repeal that provision. The bill has 81 cosponsors (all Republicans), was referred to Ways and Means, and has no further action after introduction. It is classified as an early-stage bill with 3 total actions, all on the same day. 2) The money trail: This is a tax expenditure — it reduces federal revenue by the amount of R&D spending companies immediately deduct vs. amortizing over 5 years. HR1990 does not authorize or appropriate any spending; it changes tax treatment. The estimated revenue impact is a reduction in corporate tax receipts equal to 21% of total US business R&D annually (approximately $60-80B/year based on aggregate US R&D spend of $300-400B). This is a DIRECT cash flow benefit to R&D-intensive companies with no procurement or contract mechanism — companies simply pay less tax. 3) Structural winners: The largest US R&D spenders are the direct beneficiaries. By absolute dollar, the winners are: $AMZN (~$60B R&D), $GOOGL (~$45B), $MSFT (~$30B), $AAPL (~$30B), $NVDA (~$12B), $MRK (~$14B), $PFE (~$12B), $LLY (~$11B). By sector, semiconductors, cloud software, biotech/pharma, and industrial innovators ($CAT, $DE, $GE) benefit most. Smaller-cap R&D-intensive companies benefit proportionally more relative to market cap but in smaller absolute dollars. 4) Competitive landscape: HR1990 does not pick winners by sector — it benefits any US corporation with R&D expenses. However, the structural impact favors companies with high R&D-to-revenue ratios (tech, pharma) over asset-heavy, low-R&D sectors (utilities, real estate, consumer staples). For $AMZN and $GOOGL with massive cloud R&D, the bill directly supports margin expansion without requiring top-line growth. For $UNH, the Optum health-tech R&D spend qualifies — a secondary beneficiary. 5) Timeline: HR1990 is at the earliest legislative stage (referred to committee, no hearings yet). Passage probability is low-to-moderate in the 119th Congress given the partisan nature of tax bills and limited cosponsorship (81 total, all Republican). The earliest action would be a Ways and Means markup, then House floor vote, then Senate Finance Committee consideration. Given no companion Senate bill with matching text, the legislative path is long — likely 12-18 months minimum if it gains momentum. Related bills (HR3967, S1639, S2056) show bipartisan interest in R&D expensing but no unified vehicle.